CAR T-Cell Immunotherapy for Solid Tumors (STRIvE)
Our doctors and researchers are leaders in developing chimeric antigen receptor (CAR) T-cell immunotherapies to treat children and young adults with relapsed or refractory solid tumors who are not likely to survive with standard treatments.
These phase 1 trials are called STRIvE.
Immunotherapy is an experimental new cancer treatment that uses the immune system to fight disease. Read more about how T-cell immunotherapy works.
Contact Us
For more information, call 206-987-2106 or send us an email.
CAR T-Cell Therapy for Solid Tumors: STRIvE
-
Seattle Children’s is testing CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors who are not likely to survive with standard treatments.
The trial is called STRIvE-01. In this trial, the patient’s own T cells are reprogrammed to recognize and target the protein EGFR, which is expressed by many childhood solid tumors, including sarcomas, kidney tumors and neuroblastoma.
The study began in August 2018 and is currently enrolling patients.
- Read more about the STRIvE-01 protocol at clinicaltrials.gov.
- Learn more about this and other clinical trials at Seattle Children’s.
- For more information, call 206-987-2106 or send us an email.
What is the goal of the STRIvE studies?
The STRIvE studies are phase 1 clinical trials. Phase 1 trials focus on finding out how much of a therapy to give, how to give it, how often to give it and when side effects occur. Through the STRIvE studies, researchers are working to answer these questions:
- Is T-cell therapy safe to give to children and young adults with relapsed or refractory solid tumors?
- What is the best dose of CAR T cells for children and young adults with solid tumors?
- Does T-cell therapy work against solid tumors?
Who can join the STRIvE studies?
The STRIvE studies are for children and young adults who:
- Have relapsed or refractory solid tumors
- Tumor must express EGFR
- Are ages 0 to 26 years old
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
Who is leading these trials?
Dr. Catherine (Katie) Albert is a doctor in the Cancer and Blood Disorders Center at Seattle Children’s Hospital and an investigator in the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.
T-cell trials at Seattle Children’s use methods developed by Seattle Children's Therapeutics at Seattle Children’s Research Division.
Are there studies for other childhood cancers?
STRIvE is one of our many T-cell immunotherapy trials focused on using the immune system to offer better treatment options for children and young adults with cancers, including:
- Leukemia and lymphoma (PLAT and HA-1 therapy)
- Brain and central nervous system tumors (BrainChild)
- Osteosarcoma (ENLIGHTen-01)
Contact Us
For more information, call 206-987-2106 or send us an email.
Learn More
- Learn more about our Bone Tumor and Sarcoma Clinic.
- Find other cancer clinical trials at Seattle Children’s:
- On our Current Research Studies
- On ClinicalTrials.gov. Read our guide about searching for trials on ClinicalTrials.gov (PDF).
- Learn about Seattle Children's Therapeutics.
Updated April 2023.
If you are interested in supporting the advancement of immunotherapy and cancer research at Seattle Children’s, please visit our donation page.
